title: Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
authors.affiliation: Gynecology Unit, Royal Marsden Hospital, London and Surrey, UK.
authors.forename: Liz Y
authors.initials: LY
authors.lastname: Han
authors.forename: Vasilios
authors.initials: V
authors.lastname: Karavasilis
authors.forename: Tom van
authors.initials: Tv
authors.lastname: Hagen
authors.forename: Shibani
authors.initials: S
authors.lastname: Nicum
authors.forename: Karen
authors.initials: K
authors.lastname: Thomas
authors.forename: Michelle
authors.initials: M
authors.lastname: Harrison
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Papadopoulos
authors.forename: Peter
authors.initials: P
authors.lastname: Blake
authors.forename: Desmond P J
authors.initials: DP
authors.lastname: Barton
authors.forename: Martin
authors.initials: M
authors.lastname: Gore
authors.forename: Stan B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018394:CA-125 Antigen / Q000097:blood*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors
chemical_list: D018394:CA-125 Antigen